3-phosphoinositide-dependent protein kinase 1 — Drug Target

All drugs that target 3-phosphoinositide-dependent protein kinase 1 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Moderate Risk QT Prolonging Agents

Marketed (2)

• Sutent · Pfizer · Moderate Risk QT Prolonging Agents · Oncology
  Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT.
• Sunitinib Malate · Pfizer · Moderate Risk QT Prolonging Agents · Oncology
  Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET.